Claims

1. Pharmaceutical composition for a sustained release of an active ingredient for at least 2 months, comprising:

- lanreotide as the active ingredient,
- a hydrosoluble co-solvent, and
- water,

the pH ranging from 4.0 to 7.5.

2. Pharmaceutical composition according to claim 1, wherein lanreotide is present in a concentration ranging from 35 to 55 % by weight relative to the total weight of the composition.

3. Pharmaceutical composition according to any one of the preceding claims, wherein the co-solvent is present in a concentration ranging from 10 to 25 % by weight relative to the total weight of the composition.

4. Pharmaceutical composition according to any one of the preceding claims, wherein the pH is ranging from 4.0 to 6.0, and more preferably from 4.8 to 5.4.

5. Pharmaceutical composition according to any one of the preceding claims, comprising an optional pH modifier.

6. Pharmaceutical composition according to any one of the preceding claims, comprising a pH modifier.

7. Pharmaceutical composition according to calim 6, comprising a pH modifier which is different from the co-solvent.

8. Pharmaceutical composition according to claim 5 to 7, wherein the pH modifier is selected from acetic acid, citric acid, lactic acid, phosphoric acid, hydrochloric acid, stearic acid and pamoic acid.

9. Pharmaceutical composition according to any one of the preceding claims, which is free of any non hydrosoluble, biocompatible and/or biodegradable, (co)polymer.

10. Pharmaceutical composition according to any of the preceding claims, which contains other additives selected from stabilizers, antioxidants and surfactants.

11. Pharmaceutical composition according to claim 10, wherein the amount in weight of these additives is lower than 5.0 % of the pharmaceutical composition, preferably lower than 1.0 %.

12. Pharmaceutical composition according to any of the preceding claims, which is administered by the parenteral route.

13. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 2 to 6 months in humans.

14. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 3 months in humans.

15. Pharmaceutical composition according to any of the preceding claims, for use in the treatment of acromegaly or NET.

Claims

1. Pharmaceutical composition for a sustained release of an active ingredient for at least 2 months, comprising:

- lanreotide as the active ingredient,

- a hydrosoluble co-solvent, and
- water,

the pH ranging from 4.0 to 7.5, wherein the co-solvent is present in a concentration ranging from 10 to 25 % by weight relative to the total weight of the composition.

2. Pharmaceutical composition according to claim 1, wherein lanreotide is present in a concentration ranging from 35 to 55 % by weight relative to the total weight of the composition.

3. Pharmaceutical composition according to any one of the preceding claims, wherein the pH is ranging from 4.0 to 6.0, and more preferably from 4.8 to 5.4.

4. Pharmaceutical composition according to any one of the preceding claims, comprising an optional pH modifier.

5. Pharmaceutical composition according to any one of the preceding claims, comprising a pH modifier.

6. Pharmaceutical composition according to claim 5, comprising a pH modifier which is different from the co-solvent.

7. Pharmaceutical composition according to claims 4 to 6, wherein the pH modifier is selected from acetic acid, citric acid, lactic acid, phosphoric acid, hydrochloric acid, stearic acid and pamoic acid.

8. Pharmaceutical composition according to any one of the preceding claims, which is free of any non hydrosoluble, biocompatible and/or biodegradable, (co)polymer.

9. Pharmaceutical composition according to any of the preceding claims, which contains other additives selected from stabilizers, antioxidants and surfactants.

10. Pharmaceutical composition according to claims 9, wherein the amount in weight of these additives is lower than 5.0 % of the pharmaceutical composition, preferably lower than 1.0 %.

11. Pharmaceutical composition according to any of the preceding claims, which is administered by the parenteral route.

12. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 2 to 6 months in humans.

13. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 3 months in humans.

14. Pharmaceutical composition according to any of the preceding claims, for use in the treatment of acromegaly or NET.